Detection of circulatory microRNAs in prostate cancer

Methods in Molecular Biology

Volumn 1238, Issue , 2015, Pages 523-538

  Srivastava, Anvesha ^a   Goldberger, Helle ^a   Afzal, Zainab ^a   Suy, Simeng ^a   Collins, Sean P ^a   Kumar, Deepak ^a  

^a NONE

Author keywords

MicroRNA; Plasma; Prostate cancer; Serum; Urine

Indexed keywords

MICRORNA; TAQ POLYMERASE;

ARTICLE; BODY FLUID; CONTROLLED STUDY; LIMIT OF QUANTITATION; NONHUMAN; ORGAN CIRCULATION; PRIORITY JOURNAL; PROSTATE CANCER; RNA ANALYSIS; RNA ISOLATION; RNA STABILITY; SERUM; URINE; BLOOD; BLOOD ANALYSIS; GENETICS; HUMAN; MALE; METABOLISM; PROCEDURES; PROSTATE TUMOR; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION; STANDARD; STANDARDS; URINALYSIS;

BLOOD CHEMICAL ANALYSIS; HUMANS; MALE; MICRORNAS; PROSTATIC NEOPLASMS; REAL-TIME POLYMERASE CHAIN REACTION; REFERENCE STANDARDS; REVERSE TRANSCRIPTION; TAQ POLYMERASE; URINALYSIS;

EID: 84955386632     PISSN: 10643745     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-4939-1804-1_27     Document Type: Article

References (38)

1. Siegel R, Naishadham D, Jemal A (2013) Cancer statistics, 2013. CA Cancer J Clin 63:11–30
2. Yates LA, Norbury CJ, Gilbert RJ (2013) The long and short of microRNA. Cell 153: 516–519
3. Ma R, Jiang T, Kang X (2012) Circulating microRNAs in cancer: origin, function and application. J Exp Clin Cancer Res 31:38
4. Mahn R, Heukamp LC, Rogenhofer S, von Ruecker A, Muller SC et al (2011) Circulating microRNAs (miRNA) in serum of patients with prostate cancer. Urology 77(1265):1265. e9–1265.e16
5. Sanders I, Holdenrieder S, Walgenbach- Brunagel G, von Ruecker A, Kristiansen G et al (2012) Evaluation of reference genes for the analysis of serum miRNA in patients with prostate cancer, bladder cancer and renal cell carcinoma. Int J Urol 19(11):1017–1025
6. Zhang HL, Yang LF, Zhu Y, Yao XD, Zhang SL et al (2011) Serum miRNA-21: elevated levels in patients with metastatic hormonerefractory prostate cancer and potential predictive factor for the efficacy of docetaxel-based chemotherapy. Prostate 71:326–331
7. Pang Y, Young CY, Yuan H (2010) MicroRNAs and prostate cancer. Acta Biochim Biophys Sin (Shanghai) 42:363–369
8. Lawrie CH, Gal S, Dunlop HM, Pushkaran B, Liggins AP et al (2008) Detection of elevated levels of tumour-associated microRNAs in serum of patients with diffuse large B-cell lymphoma. Br J Haematol 141:672–675
9. Chen X, Ba Y, Ma L, Cai X, Yin Y et al (2008) Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res 18: 997–1006
10. Creemers EE, Tijsen AJ, Pinto YM (2012) Circulating microRNAs: novel biomarkers and extracellular communicators in cardiovascular disease? Circ Res 110:483–495
11. El-Hefnawy T, Raja S, Kelly L, Bigbee WL, Kirkwood JM et al (2004) Characterization of amplifiable, circulating RNA in plasma and its potential as a tool for cancer diagnostics. Clin Chem 50:564–573
12. Valadi H, Ekstrom K, Bossios A, Sjostrand M, Lee JJ et al (2007) Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. Nat Cell Biol 9:654–659
13. Wang K, Zhang S, Weber J, Baxter D, Galas DJ (2010) Export of microRNAs and microRNAprotective protein by mammalian cells. Nucleic Acids Res 38:7248–7259
14. Huang X, Liang M, Dittmar R, Wang L (2013) Extracellular microRNAs in urologic malignancies: chances and challenges. Int J Mol Sci 14:14785–14799
15. Borer RA, Lehner CF, Eppenberger HM, Nigg EA (1989) Major nucleolar proteins shuttle between nucleus and cytoplasm. Cell 56: 379–390
16. Maggi LB, Kuchenruether M, Dadey DYA, Schwope RM, Grisendi S et al (2008) Nucleophosmin serves as a rate-limiting nuclear export chaperone for the mammalian ribosome. Mol Cell Biol 28:7050–7065
17. Vickers K, Palmisano B, Shoucri B, Shamburek R, Remaley A (2011) MicroRNAs are transported in plasma and delivered to recipient cells by high-density lipoproteins. Nat Cell Biol 13:423–433
18. Zomer A, Vendrig T, Hopmans ES, Mv E, Middeldorp JM et al (2010) Exosomes: fit to deliver small RNA. Commun Integr Biol 3:447–450
19. Srivastava A, Goldberger H, Dimtchev A, Ramalinga M, Chijioke J et al (2013) MicroRNA profi ling in prostate cancer—the diagnostic potential of urinary miR-205 and miR-214. PLoS One 8:e76994
20. Zen K, Zhang C-Y (2012) Circulating microRNAs: a novel class of biomarkers to diagnose and monitor human cancers. Med Res Rev 32:326–348
21. Heneghan HM, Miller N, Kelly R, Newell J, Kerin MJ (2010) Systemic miRNA-195 differentiates breast cancer from other malignancies and is a potential biomarker for detecting noninvasive and early stage disease. Oncologist 15:673–682
22. Mestdagh P, Van Vlierberghe P, De Weer A, Muth D, Westermann F et al (2009) A novel and universal method for microRNA RT-qPCR data normalization. Genome Biol 10:R64
23. Andersen CL, Jensen JL, Ãrntoft TF (2004) Normalization of real-time quantitative reverse transcription-PCR data: a model-based varianceestimation approach to identify genes suited for normalization, applied to bladder and colon cancer data sets. Cancer Res 64:5245–5250
24. Mitchell PS, Parkin RK, Kroh EM, Fritz BR, Wyman SK et al (2008) Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci U S A 105: 10513–10518
25. Lodes MJ, Caraballo M, Suciu D, Munro S, Kumar A et al (2009) Detection of cancer with serum miRNAs on an oligonucleotide microarray. PLoS One 4:e6229
26. Brase JC, Johannes M, Schlomm T, Fälth M, Haese A et al (2011) Circulating miRNAs are correlated with tumor progression in prostate cancer. Int J Cancer 128:608–616
27. Yaman Agaoglu F, Kovancilar M, Dizdar Y, Darendeliler E, Holdenrieder S et al (2011) Investigation of miR-21, miR-141, and miR- 221 in blood circulation of patients with prostate cancer. Tumor Biol 32:583–588
28. Moltzahn F, Olshen AB, Baehner L, Peek A, Fong L et al (2011) Microfl uidic-based multiplex qRT-PCR identifi es diagnostic and prognostic microRNA signatures in the sera of prostate cancer patients. Cancer Res 71: 550–560
29. Zheng C, Yinghao S, Li J (2012) MiR-221 expression affects invasion potential of human prostate carcinoma cell lines by targeting DVL 2. Med Oncol 29:815–822
30. Gonzales JC, Fink LM, Goodman OB Jr, Symanowski JT, Vogelzang NJ et al (2011) Comparison of circulating microRNA 141 to circulating tumor cells, lactate dehydrogenase, and prostate-specifi c antigen for determining treatment response in patients with metastatic prostate cancer. Clin Genitourin Cancer 9:39–45
31. Selth LA, Townley S, Gillis JL, Ochnik AM, Murti K et al (2012) Discovery of circulating microRNAs associated with human prostate cancer using a mouse model of disease. Int J Cancer 131:652–661
32. Shen J, Hruby GW, McKiernan JM, Gurvich I, Lipsky MJ et al (2012) Dysregulation of circulating microRNAs and prediction of aggressive prostate cancer. Prostate 72: 1469–1477
33. Chen Z-H, Zhang G-L, Li H-R, Luo J-D, Li Z-X et al (2012) A panel of fi ve circulating microRNAs as potential biomarkers for prostate cancer. Prostate 72:1443–1452
34. Nguyen HCN, Xie W, Yang M, Hsieh C-L, Drouin S et al (2013) Expression differences of circulating microRNAs in metastatic castration resistant prostate cancer and low-risk, localized prostate cancer. Prostate 73:346–354
35. Cheng HH, Mitchell PS, Kroh EM, Dowell AE, Chéry L et al (2013) Circulating microRNA profi ling identifi es a subset of metastatic prostate cancer patients with evidence of cancerassociated hypoxia. PLoS One 8:e69239
36. Selth LA, Townley SL, Bert AG, Stricker PD, Sutherland PD et al (2013) Circulating microRNAs predict biochemical recurrence in prostate cancer patients. Br J Cancer 109: 641–650
37. Watahiki A, Macfarlane R, Gleave M, Crea F, Wang Y et al (2013) Plasma miRNAs as biomarkers to identify patients with castrationresistant metastatic prostate cancer. Int J Mol Sci 14:7757–7770
38. Bryant RJ, Pawlowski T, Catto JWF, Marsden G, Vessella RL et al (2012) Changes in circulating microRNA levels associated with prostate cancer. Br J Cancer 106:768–774